Mirdametinib + BGB-3245 in Advanced Solid Tumors

Clinical trial NCT05580770 · TERMINATED

Trial details

NCT number: NCT05580770
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumor

Start date: 2023-02-03
Primary completion: 2025-01-15
Enrollment: 23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.